Screener
Mineralys Therapeutics, Inc. MLYS Research and development expenses
Research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept mlys:AccruedResearchAndDevelopmentCostsCurrent.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
FAQ
- What is Mineralys Therapeutics, Inc.'s research and development expenses?
- Mineralys Therapeutics, Inc. (MLYS) reported research and development expenses of $4.59M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s research and development expenses changed year-over-year?
- Mineralys Therapeutics, Inc.'s research and development expenses decreased by 52.5% year-over-year, from $9.66M to $4.59M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s research and development expenses?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s research and development expenses has grown at a -10.6% compound annual growth rate (CAGR), from $4.85M to $3.46M.
- What does research and development expenses mean?
- This represents liabilities incurred for research and development activities that have been performed but not yet invoiced or paid. It serves as a leading indicator of near-term cash outflows required to sustain ongoing clinical trials and drug development pipelines.
Ask your AI about Mineralys Therapeutics, Inc.'s research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude